Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro(Aichi Cancer Center), Hyun Cheol Chung(Yonsei University), Veena Shankaran(University of Washington), Ravit Geva(Tel Aviv Sourasky Medical Center), Daniel V.T. Catenacci(University of Chicago), Shilpa Gupta(University of Minnesota), Joseph P. Eder(Yale University), Talia Golan(Sheba Medical Center), Dung T. Le(Johns Hopkins University), Barbara Burtness(Fox Chase Cancer Center), Autumn J. McRee(University of North Carolina at Chapel Hill), Chia‐Chi Lin(National Taiwan University Hospital), Kumudu Pathiraja(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jared Lunceford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kenneth Emancipator(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jonathan Juco(Merck & Co., Inc., Rahway, NJ, USA (United States)), Minori Koshiji(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yung‐Jue Bang(Seoul National University)
Cited by 1,130Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis